Mitomycin-C in hyperopic photorefractive keratectomy.
OBJECTIVE
To evaluate the effects of topical mitomycin-C (MMC) after hyperopic photorefractive keratectomy (PRK).


METHODS
Private practice, Siena, Italy.


METHODS
In this prospective study, a sponge with 0.2 mg/mL MMC or balanced salt solution (controls) was placed on the stroma for 45 seconds after PRK performed using a Technolas 217z laser. After epithelialization, fluorometholone 0.1% eyedrops were used for 4 months in both groups.


RESULTS
The MMC group comprised 88 eyes (mean spherical equivalent [SE] +3.51 diopters [D] +/- 1.04) and the control group, 91 eyes (mean SE +3.50 +/- 1.03 D). At 18 months, the mean SE was -0.10 +/- 0.37 D and 0.22 +/- 0.70 D, respectively, and the mean defocus equivalent, 0.34 +/- 0.32 D and 0.69 +/- 0.74 D, respectively (both P<.05). The mean best spectacle-corrected visual acuity (BSCVA) was 0.06 +/- 0.08 logMAR in the MMC group and 0.08 +/- 0.10 logMAR in the control group; 2 eyes and 11 eyes, respectively, lost more than 0.1 logMAR of BSCVA. The mean uncorrected visual acuity (UCVA) was 0.13 +/- 0.11 logMAR in the MMC group and 0.21 +/- 0.20 logMAR in the control group (P<.05). The UCVA was better than 20/40 in 94% of eyes and 80% of eyes, respectively. The efficacy index was 0.87 and 0.67, respectively. Haze at 18 months was 0.05 +/- 0.11 in the MMC group and 0.23 +/- 0.46 in the control group (P<.05). No endothelial damage was observed in either group.


CONCLUSIONS
Mitomycin-C prevented haze formation and improved predictability and efficacy. No adverse effects occurred.
Leccisotti
Antonio
A
Ophthalmic Surgery Unit, Casa di Cura Rugani, Siena, Italy. leccisotti@libero.it
D000287:Administration, Topical; D000328:Adult; D000477:Alkylating Agents / Q000008:administration & dosage*; D001251:Astigmatism / Q000601:surgery; D002452:Cell Count; D003318:Corneal Opacity / Q000517:prevention & control; D003319:Corneal Stroma / Q000187:drug effects*; D004311:Double-Blind Method; D004728:Endothelium, Corneal / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006956:Hyperopia / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D018903:Photorefractive Keratectomy; D011446:Prospective Studies; D014786:Vision Disorders / Q000517:prevention & control; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
D000477:Alkylating Agents; D016685:Mitomycin